418 related articles for article (PubMed ID: 22262002)
21. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.
Grey A; Bolland M; Fenwick S; Horne A; Gamble G; Drury PL; Reid IR
Eur J Endocrinol; 2014 Feb; 170(2):255-62. PubMed ID: 24217934
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
[TBL] [Abstract][Full Text] [Related]
23. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.
Palermo A; D'Onofrio L; Eastell R; Schwartz AV; Pozzilli P; Napoli N
Osteoporos Int; 2015 Aug; 26(8):2073-89. PubMed ID: 25910746
[TBL] [Abstract][Full Text] [Related]
24. Bone disorders associated with diabetes mellitus and its treatments.
Cortet B; Lucas S; Legroux-Gerot I; Penel G; Chauveau C; Paccou J
Joint Bone Spine; 2019 May; 86(3):315-320. PubMed ID: 30098423
[TBL] [Abstract][Full Text] [Related]
25. Osteoporosis and risk of fracture in patients with diabetes: an update.
Montagnani A; Gonnelli S; Alessandri M; Nuti R
Aging Clin Exp Res; 2011 Apr; 23(2):84-90. PubMed ID: 21743287
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and fractures: an overshadowed association.
Khazai NB; Beck GR; Umpierrez GE
Curr Opin Endocrinol Diabetes Obes; 2009 Dec; 16(6):435-45. PubMed ID: 19779334
[TBL] [Abstract][Full Text] [Related]
27. Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism.
Lee HS; Hwang JS
Curr Diab Rep; 2020 Nov; 20(12):78. PubMed ID: 33247351
[TBL] [Abstract][Full Text] [Related]
28. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
Alba M; Xie J; Fung A; Desai M
Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
[TBL] [Abstract][Full Text] [Related]
29. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
Wolverton D; Blair MM
Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
[TBL] [Abstract][Full Text] [Related]
30. Bone health in diabetes: considerations for clinical management.
Adami S
Curr Med Res Opin; 2009 May; 25(5):1057-72. PubMed ID: 19292601
[TBL] [Abstract][Full Text] [Related]
31. Diabetes and fragility fractures - a burgeoning epidemic?
Epstein S; LeRoith D
Bone; 2008 Jul; 43(1):3-6. PubMed ID: 18486581
[TBL] [Abstract][Full Text] [Related]
32. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
[TBL] [Abstract][Full Text] [Related]
33. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes.
Botella Martínez S; Varo Cenarruzabeitia N; Escalada San Martin J; Calleja Canelas A
Endocrinol Nutr; 2016 Nov; 63(9):495-501. PubMed ID: 27481443
[TBL] [Abstract][Full Text] [Related]
34. Hip geometry in diabetic women: implications for fracture risk.
Garg R; Chen Z; Beck T; Cauley JA; Wu G; Nelson D; Lewis B; LaCroix A; LeBoff MS
Metabolism; 2012 Dec; 61(12):1756-62. PubMed ID: 22726843
[TBL] [Abstract][Full Text] [Related]
35. Diabetes medications and bone.
Grey A
Curr Osteoporos Rep; 2015 Feb; 13(1):35-40. PubMed ID: 25433437
[TBL] [Abstract][Full Text] [Related]
36. Type 2 diabetes mellitus and fracture risk.
Dede AD; Tournis S; Dontas I; Trovas G
Metabolism; 2014 Dec; 63(12):1480-90. PubMed ID: 25284729
[TBL] [Abstract][Full Text] [Related]
37. Bone damage in type 2 diabetes mellitus.
Carnevale V; Romagnoli E; D'Erasmo L; D'Erasmo E
Nutr Metab Cardiovasc Dis; 2014 Nov; 24(11):1151-7. PubMed ID: 25150773
[TBL] [Abstract][Full Text] [Related]
38. Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel.
Chiodini I; Gaudio A; Palermo A; Napoli N; Vescini F; Falchetti A; Merlotti D; Eller-Vainicher C; Carnevale V; Scillitani A; Pugliese G; Rendina D; Salcuni A; Bertoldo F; Gonnelli S; Nuti R; Toscano V; Triggiani V; Cenci S; Gennari L
Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2210-2233. PubMed ID: 34059385
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes and the skeleton: new insights into sweet bones.
Shanbhogue VV; Mitchell DM; Rosen CJ; Bouxsein ML
Lancet Diabetes Endocrinol; 2016 Feb; 4(2):159-73. PubMed ID: 26365605
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
Yaturu S; Bryant B; Jain SK
Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
